Palo Alto Investors LP Syndax Pharmaceuticals Inc Transaction History

Palo Alto Investors LP

$727 Million
Q3 2024

A detailed history of Palo Alto Investors LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Palo Alto Investors LP holds 405,193 shares of SNDX stock, worth $5.31 Million. This represents 1.07% of its overall portfolio holdings.

Number of Shares

405,193

Previous 405,193 -0.0%

Holding current value

$5.31 Million

Previous $8.32 Million 6.24%

% of portfolio

1.07%

Previous 1.05%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $1.33 Million - $1.66 Million	-67,407 Reduced 14.26%	405,193 $9.64 Million
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $2.03 Million - $3.05 Million	-140,000 Reduced 22.85%	472,600 $6.86 Million
Q1 2022 May 16, 2022	BUY	$14.84 - $22.15 $203,308 - $303,455	13,700 Added 2.29%	612,600 $10.6 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $2.35 Million - $3.46 Million	154,000 Added 34.61%	598,900 $13.1 Million
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $607,506 - $867,240	43,800 Added 10.92%	444,900 $8.5 Million
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $1.84 Million - $3.45 Million	136,900 Added 51.82%	401,100 $6.89 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $993,580 - $1.74 Million	65,800 Added 33.17%	264,200 $5.88 Million
Q3 2020 Nov 16, 2020	BUY	$13.39 - $17.48 $946,673 - $1.24 Million	70,700 Added 55.36%	198,400 $2.93 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $550,704 - $1.29 Million	61,600 Added 93.19%	127,700 $1.89 Million
Q1 2020 May 15, 2020	BUY	$6.65 - $12.03 $439,565 - $795,183	66,100 New	66,100 $725,000

Others Institutions Holding SNDX

# of Institutions

229

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $742M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.

Account

Palo Alto Investors LP Syndax Pharmaceuticals Inc Transaction History